Lisa A. Carey, MD, and Mark E. Robson, MD, on HER2-Negative Breast Cancer: Results From the OlympiAD Trial

2017 ASCO Annual Meeting
Tweet this page

Lisa A. Carey, MD, of the University of North Carolina, and Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, discuss phase III study findings on olaparib monotherapy vs chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation. (Abstract LBA4)

Advertisement

Advertisement



Advertisement